leisure time -WSS

leisure time

author：hotspot 2025-09-06 04:26:54 - browse：61746

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Late stage cancers on the rise after pandemic delayed screenings

hotspot

entertainment

WSS

The cancer stories no one wants to hear

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Study links childhood stress with decline in older age

'Null' research findings aren't empty of meaning. Let's publish them

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Investment in vaccine development is lagging, report finds

entertainment

leisure time

Wikipedia

Drug repurposing or repositioning? The language matters

Zyn nicotine pouches become unlikely player in latest culture war

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The cancer stories no one wants to hear

Dobbs anniversary: the lost opportunity of abortion as health care

FTC sues over Novant Health acquisition of two N.C. hospitals

Virginia high school admissions case could be legal follow

When waiting feels immoral: Empathy in the emergency department

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest on Novavax, Merck, Bluebird

focus

10 reasons why health care startups fail

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Flint parents haunted by uncertainty, fears of lead poisoning

When waiting feels immoral: Empathy in the emergency department

Wegovy leads to weight loss. Can it treat depression, too?

Personalized medicine goes far beyond genetics

hotspot

focus

entertainment

Wikipedia